Florian Rader, MD

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and learn why patients breathe easier.

Learn key hypertrophic cardiomyopathy symptoms and how echoes with Valsalva or exercise reveal hidden LVOT obstruction for accurate diagnosis.

Panelists discuss the signs, symptoms, diagnostic delays, and classification of obstructive hypertrophic cardiomyopathy, including how it differs from other forms and its implications for clinical management.

Panelists discuss the challenges and gaps in diagnosing hypertrophic cardiomyopathy, including variability in clinical practice, underdiagnosis, and opportunities to improve detection.

A panelist discusses how future improvements in resistant hypertension management will focus on overcoming medication noncompliance through long-acting injectable treatments and device-based options like renal denervation, while emphasizing best practices including accurate out-of-office blood pressure measurements and systematic treatment protocols targeting 130/80 mmHg.

A panelist discusses how aprocitentan is most beneficial for patients who have tried multiple antihypertensive medications without success, particularly those with chronic kidney disease, abnormal kidney function, or hyperkalemia who cannot tolerate other medication classes that affect electrolyte levels.

A panelist discusses how patient compliance remains the primary obstacle to blood pressure control despite effective medications being available, while clinical inertia among healthcare providers and medication side effects affecting electrolytes and kidney function add additional complexity to resistant hypertension management.

A panelist discusses how successful treatment requires selecting the right three to five medications with minimal side effects, using once-daily combination pills to maximize adherence, and engaging patients as active participants through structured home blood pressure monitoring protocols.

A panelist discusses how patient compliance remains the primary obstacle to blood pressure control despite effective medications being available, while clinical inertia among healthcare providers and medication side effects affecting electrolytes and kidney function add additional complexity to resistant hypertension management.

Dr Rader outlines the critical impact of resistant hypertension, and emphasizes the criticality of early identification of risk factors.

Dr Rader begins his contribution to a discussion surrounding resistant hypertension, defining common parameters for diagnosis.